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PATIENTS who have undergone complete hypophysectomy in the treatment of
carcinoma of the breast hardly ever show subsequent improvement when treated
with hormones such as androgens, oestrogens or cortisone analogues. This clinical
observation supports the conclusion, in most experimental animals, that after
hypophysectomy there is little or no response by breast tissue to stimulation with
oestrogens. Apart from general care and analgesics the palliation ofpatients with
advanced carcinoma of the breast uncontrolled by pituitary ablation is therefore
limited to radiotherapy, the cytotoxic drugs and possibly 3-methylcholanthrene
(Huggins and McCarthy, 1957). The effect of hypophysectomy, though satisfac-
tory in over 50 per cent of patients, seldom lasts longer than three to four years
(Luft et al., 1958; Ray and Pearson, 1956; Baron et al., 1958). Very often the
general condition of these patients is surprisingly good at the time of relapse or
when it becomes clear that hypophysectomy has not been beneficial. Attempts at
further treatment are sometimes justified. Because hormones are ineffective and
in the majority of cases radiotherapy is contra-indicated, we have studied the
effect of the aklylating agent triethylene thiophosphoramide (thiotepa). Shay
and his colleagues (Shay et al., 1953; Shay and Sun, 1955) first suggested that
thiotepa might be of benefit to patients with metastatic carcinoma of the breast.
Subsequently Bateman and her colleagues (Bateman, 1955; Bateman and Larsen,
1956) reported improvement in up to 85 per cent ofpatients so treated. It appears
that thiotepa is relatively more effective in the treatment ofmammary and ovarian
carcinoma than in lymphomas such as Hodgkin's disease or leukaemias.
METHODS
Thiotepa was dissolved in water in concentrations of 1 mg. to 5 mg. per ml.,
sterilised by Seitz filtration, stored in a refrigerator and used within three weeks
of preparation. It was given by intramuscular injection, the usual plan being to
give 5 mg. daily for five days in the first week with a similar dose in the second
week if the white cells and platelet counts were unaffected. Treatment was con-
tinued with 5 mg. I.M.I. two or three times a week for as long as possible, reducing
to 3 mg. if the white count showed signs of falling. No treatment was given if
the W.B.C.s were 3,000 c.mm. or under or the platelets below 140,000 c.mm.
Pain after injection was not usually severe but persisted for about half an hour
in some patients. The intramuscular route was chosen because of the ease ofTREATMENT OF CARCINOMA OF THE BREAST
administration, particularly in out-patients, but in one instance injections were
also given into a tumour mass and three patients had intrapleural injections of
20 mg. of thiotepa.
RESULTS
Eighteen women who had previously undergone surgical hypophysectomy,
combined with radioactive gold seed implantation, have been treated for periods
of up to 56 weeks. Eight had shown objective improvement after the operation.
Treatment with thiotepa was continued for six weeks or more in all but one
patient whose white cell and platelet counts fell precipitously after three weeks
and in whom there were signs of leuko-erythroblastic anaemia. The total dose
ofthiotepa ranged from 65 to 520 mg.
Objective improvement such as reduction in the size oflymph nodes, cutaneous
and hepatic metastases or locally recurrent tumour, was observed in 10 of the 18
patients (56 per cent). In seven (39 per cent) objective improvement was main-
tained for eight weeks or more, but in two improvement was transient and lasted
for between four and six weeks only. Although objective and subjective improve-
ment were usually related, in one patient (Case 18) there was considerable reduction
in the size ofsupra-clavicular and axillary lymph nodes for more than two months
without subjective benefit. A summary ofsome ofthe clinical findings, dosage and
toxic effects is given in Table I. Bone pain from metastases has been relieved in
four patients, obstructive jaundice in two, severe paroxysmal auricular fibrillation
caused by mediastinal and pericardial involvement in another, and peripheral
blood changes indicating leuko-erythroblastic anaemia have improved in two
instances. The duration ofimprovement has been variable. Four have maintained
objective improvement for over six months, the longest period of remission being
13 months in a woman with cutaneous metastases, the total dose ofdrug in these
women being 280, 235, 390 and 520 mg. given intermittently. In two patients
the paradox was seen of certain metastases improving whilst new ones appeared
elsewhere, a fairly common occurrence in patients with hormone sensitive tumours.
It is possibly ofsignificance that the four women who showed the most improve-
ment had all previously responded well tohypophysectomy for bc-tween six months
and two years before receiving thiotepa, and it may be that their tumours were
intrinsically more responsive to any type of treatment. The histological appear-
ances were not related to the therapeutic response.
Toxic Effects
Apart from pain at the site of injection the only troublesome side effect was
haematopoietic depression. The white countfellto below 3,000 c.m. in five patients,
the two lowest being 1,800 c.mm. after a total dose of 155 mg., and 1,900 per c.mm.
after 520 mg., the granulocytes being more severely depressed than the lympho-
cytes. In none of the women in this series were the lymphocytes selectively in-
volved. Recovery from mild granulocytopenia usually occurred within 10-21 days
of stopping treatment. In Case 2 the white cell count rose from 1,900 to 6,200
per c.mm., with a normal differential by the fifteenth day. A significant fall in
platelet count to 120,000 c.mm. or under was observed in five patients, the
lowest being 86,000 after 155 mg. thiotepa given over a period of 11 weeks. No
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haemorrhagic complications developed. The most rapid and severe bone marrow
depression seems most likely to occur when there are leuko-erythroblastic changes
but this is not necessarily a contraindication to treatment since improvement
may result. No significant fall in haemoglobin levels could be attributed to
treatment during the time these patients came under observation.
DISCUSSION
In this group of patients in whom all other forms of treatment from mastec-
tomy to hypophysectomy had failed to control the tumour, thiotepa has led to
significant objective improvement in about one third for over six months at a
time when rapid deterioration was anticipated. The prolongation oflife and relief
of symptoms has sometimes been significant and worthwhile and the unpleasant
consequence of treatment minimal. Although the degree of improvement to be
expected in these patients is relatively small, the disappearance of obstructive
jaundice and control of troublesome metastases has allowed two women who had
previously been confined to bed to return to house work. Constant supervision,
regular blood counts and individual adjustment of dosage are of course essential,
and the improvement is no more than temporary, but the response compares
favourably with the effect of analgesics and the usual care given to the dying
patient. In any case the use of thiotepa does not exclude the administration of
morphia or cocaine as the comfort of the patient demands. Batemen and Larsen
(1956) claimed that 80 per cent oftheir patients with breast cancer were improved
even to the extent ofrecalcification ofbone lesions. They emphasised that a slow
response was not unusual and that, as with hormones, maintenance treatment
was desirable. On the other hand Ultmann et al. (1957) found intravenous thiotepa
to be effective in the treatment of ovarian carcinoma, but none of the patients
with mammary cancer improved. There was a high incidence of haematological
depression, 47 per cent of patients developing an abnormal blood picture while
17 per cent had clinical manifestations of bleeding or toxicity. Leonard, Israels
and Wilkinson (1956) also encountered a higher incidence ofside effects in patients
with a variety of lymphomas who were given doses such as 25 mg. per injection.
It seems probable that the use of relatively small doses given intramuscularly for
as long as possible is less toxic, more effective and to be preferred to more inten-
sive treatment intravenously. Although the value of triethylene thiophosphor-
amide is limited, a good response in some of these hypophysectomised women
with advanced carcinoma of the breast suggests that such treatment should be
tried in certain patients when other more effective remedies have failed.
SUMMARY
Eighteen women with advanced metastatic carcinoma of the breast have been
treated with intramuscular triethylene thiophosphoramide in doses ofup to a total
of 560 mg. for periods ofup to 56 weeks. Objective improvement was noted in 10
patients (56 per cent), in seven of whom improvement was maintained for eight
weeks or more with a maximum of56 weeks. It is considered that prolonged intra-
muscular treatment with thiotepa is worthwhile in patients who have failed to
respond to, or relapsed after, hormone therapy or endocrine surgery.
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